Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by myelin destruction and axonal damage of the brain, optic nerves and spinal cord.1 MS affects approximately 2.3 million people worldwide.2
Recently, the US Food and Drug Administration approved Kesimpta® (ofatumumab) as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome (CIS), relapsing-remitting disease, and active secondary progressive disease, in adults.3
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home with an autoinjector pen, addressing significant unmet needs for people living with RMS.3
We spoke with Dr. Robert Shin, Professor of Neurology at Georgetown University in Washington, D.C. and the Director of the Georgetown Multiple Sclerosis and Neuroimmunology Center, and patient, Kerry, who was diagnosed with relapsing MS in 2012.
Learn more at Kesimpta.com